Genetic Technologies Limited

Symbol: GTG.AX

ASX

0.125

AUD

Market price today

  • -0.8258

    P/E Ratio

  • -0.1243

    PEG Ratio

  • 16.53M

    MRK Cap

  • 0.00%

    DIV Yield

Genetic Technologies Limited (GTG-AX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

-0.38%

Operating Profit Margin

-1.20%

Net Profit Margin

-1.44%

Return on Assets

-2.15%

Return on Equity

-2.02%

Return on Capital Employed

-3.00%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO:Mr. Simon Morriss
Full-time employees:60
City:Fitzroy
Address:60-66 Hanover Street
IPO:1988-01-31
CIK:

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

General Outlook

When we look at how much money they make before expenses, they keep -0.376% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -1.197%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -1.437%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -2.146% return, is a testament to Genetic Technologies Limited's adeptness in optimizing resource deployment. Genetic Technologies Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -2.019%. Furthermore, the proficiency of Genetic Technologies Limited in capital utilization is underscored by a remarkable -3.000% return on capital employed.

Stock Prices

Genetic Technologies Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.12, while its low point bottomed out at $0.11. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Genetic Technologies Limited's stock market.

Liquidity Ratios

Analyzing GTG.AX liquidity ratios reveals its financial health of the firm. The current ratio of 167.04% gauges short-term asset coverage for liabilities. The quick ratio (141.58%) assesses immediate liquidity, while the cash ratio (108.98%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio167.04%
Quick Ratio141.58%
Cash Ratio108.98%

Profitability Ratios

GTG.AX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -144.95% underscores its earnings before tax deductions. The effective tax rate stands at 0.86%, revealing its tax efficiency. The net income per EBT, 99.14%, and the EBT per EBIT, 121.08%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -119.71%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-144.95%
Effective Tax Rate0.86%
Net Income per EBT99.14%
EBT per EBIT121.08%
EBIT per Revenue-119.71%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.67, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 1133.61% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding142
Days of Inventory Outstanding8
Operating Cycle40.52
Days of Payables Outstanding40
Receivables Turnover11.34
Payables Turnover9.08
Inventory Turnover43.85
Fixed Asset Turnover29.46
Asset Turnover1.49

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.06, and free cash flow per share, -0.06, depict cash generation on a per-share basis. The cash per share value, 0.03, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.53, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.06
Free Cash Flow per Share-0.06
Cash per Share0.03
Operating Cash Flow Sales Ratio-0.53
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-17.58
Short Term Coverage Ratio-22.54
Capital Expenditure Coverage Ratio-163.91
Dividend Paid and Capex Coverage Ratio-163.91

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 4.52%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.08, we discern the balance between debt and equity financing. The long-term debt to capitalization, 1.72%, and total debt to capitalization, 7.36%, ratios shed light on its capital structure. An interest coverage of -357.29 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio4.52%
Debt Equity Ratio0.08
Long Term Debt to Capitalization1.72%
Total Debt to Capitalization7.36%
Interest Coverage-357.29
Cash Flow to Debt Ratio-17.58
Company Equity Multiplier1.76

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.10, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.12, reflects the portion of profit attributed to each share. The book value per share, 0.11, represents the net asset value distributed per share, while the tangible book value per share, 0.07, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.10
Net Income Per Share-0.12
Book Value Per Share0.11
Tangible Book Value Per Share0.07
Shareholders Equity Per Share0.11
Interest Debt Per Share0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 5536.33%, indicates top-line expansion, while the gross profit growth, 2792.02%, reveals profitability trends. EBIT growth, 39.25%, and operating income growth, 39.25%, offer insights into operational profitability progression.

cards.indicatorcards.value
Revenue Growth5536.33%
Gross Profit Growth2792.02%
EBIT Growth39.25%
Operating Income Growth39.25%
Net Income Growth1.07%
Weighted Average Shares Growth7.91%
Weighted Average Shares Diluted Growth7.91%
Operating Cash Flow Growth0.06%
Free Cash Flow Growth7.63%
10-Year Revenue Growth per Share-88.96%
5-Year Revenue Growth per Share848.28%
3-Year Revenue Growth per Share7533.09%
10-Year Operating CF Growth per Share95.22%
5-Year Operating CF Growth per Share69.21%
3-Year Operating CF Growth per Share69.16%
10-Year Net Income Growth per Share95.82%
5-Year Net Income Growth per Share65.53%
3-Year Net Income Growth per Share70.17%
10-Year Shareholders Equity Growth per Share-84.01%
5-Year Shareholders Equity Growth per Share-7.90%
3-Year Shareholders Equity Growth per Share165.16%
Receivables Growth125.37%
Inventory Growth417.57%
Asset Growth-9.45%
Book Value per Share Growth-29.29%
Debt Growth219.81%
R&D Expense Growth-77.31%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 18,026,836.5, captures the company's total value, considering both debt and equity. Income quality, 0.83, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.13, gauges operational efficiency, while the research and development to revenue, 12.38%, highlights investment in innovation. The ratio of intangibles to total assets, 24.48%, indicates the value of non-physical assets, and capex to operating cash flow, 0.18%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value18,026,836.5
Income Quality0.83
Sales General and Administrative to Revenue0.13
Research and Development to Revenue12.38%
Intangibles to Total Assets24.48%
Capex to Operating Cash Flow0.18%
Capex to Revenue-0.17%
Capex to Depreciation-2.59%
Stock-Based Compensation to Revenue2.45%
Graham Number0.54
Return on Tangible Assets-104.74%
Graham Net Net0.04
Working Capital7,185,750
Tangible Asset Value7,525,211
Net Current Asset Value6,804,134
Average Receivables1,306,570.5
Average Payables995,904
Average Inventory362,021.5
Days Sales Outstanding7
Days Payables Outstanding71
Days of Inventory On Hand27
ROIC-90.25%
ROE-1.05%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.12, and the price to book ratio, 3.12, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.36, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -2.54, and price to operating cash flows, -2.23, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.12
Price to Book Ratio3.12
Price to Sales Ratio1.36
Price Cash Flow Ratio-2.23
Price Earnings to Growth Ratio-0.12
Enterprise Value Multiple-1.45
Price Fair Value3.12
Price to Operating Cash Flow Ratio-2.23
Price to Free Cash Flows Ratio-2.54
Price to Tangible Book Ratio2.27
Enterprise Value to Sales1.74
Enterprise Value Over EBITDA-1.80
EV to Operating Cash Flow-1.85
Earnings Yield-46.36%
Free Cash Flow Yield-38.43%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Genetic Technologies Limited (GTG.AX) on the ASX in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.826 in 2024.

What is the ticker symbol of Genetic Technologies Limited stock?

The ticker symbol of Genetic Technologies Limited stock is GTG.AX.

What is company IPO date?

IPO date of Genetic Technologies Limited is 1988-01-31.

What is company current share price?

Current share price is 0.125 AUD.

What is stock market cap today?

The market cap of stock today is 16527125.000.

What is PEG ratio in 2024?

The current -0.124 is -0.124 in 2024.

What is the number of employees in 2024?

In 2024 the company has 60.